|

Tulmimetostat Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: DZR123, Pembrolizumab

Pipeline

Phase 1/2: 3

Top Sponsors

  • Novartis Pharmaceuticals2
  • VA Office of Research and Development1

Indications

  • Cancer3
  • Lung Cancer2
  • Ovarian Clear Cell Carcinoma1
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)1
  • Prostatic Neoplasms, Castration-Resistant1

Long Beach, California1 trial

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

VA Long Beach Healthcare System, Long Beach, CA

Phase 1/2

Atlanta, Georgia1 trial

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Winship Cancer Institute of Emory University

Phase 1/2

Wichita, Kansas1 trial

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Wichita Urology Group PA

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.